Targeting the androgen receptor--theory and practice.
Journal Article (Journal Article)
Intensive investigation during the past 2 decades has led to an improved knowledge of the biology of the androgen receptor and a better understanding of how to assess for disease progression and the apparent existence of castrate-resistant prostate cancer. The result has been the clinical development of a new generation of hormonal therapy agents for achieving the androgen deprivation necessary to achieve castrate levels of circulating testosterone. It has also resulted in the realization that it is probably time to move away from using terms such as "hormone-refractory" and "androgen-independent" prostate cancer, given the clear evidence that significant, effective, ongoing suppression of testosterone, using better drugs and better assays, will continue to be the standard of care.
Full Text
Duke Authors
Cited Authors
- Dreicer, R; Gleave, M; Kibel, AS; Thrasher, JB; Moul, JW
Published Date
- November 2011
Published In
Volume / Issue
- 78 / 5 Suppl
Start / End Page
- S482 - S484
PubMed ID
- 22054919
Electronic International Standard Serial Number (EISSN)
- 1527-9995
Digital Object Identifier (DOI)
- 10.1016/j.urology.2011.05.052
Language
- eng
Conference Location
- United States